肝硬化及其并发症的诊断与管理:综述
综述汇总肝硬化的常见病因、无创诊断(弹性成像≥15 kPa可确诊)、并发症自然史及关键随机试验证据。一线治疗包括卡维地洛或普萘洛尔预防静脉曲张出血、乳果糖治疗肝性脑病、醛固酮拮抗剂联合袢利尿剂治疗腹水、特利加压素治疗肝肾综合征。
要点
- 弹性成像肝硬度≥15 kPa通常可确认肝硬化,约40%患者以肝性脑病或腹水等并发症首诊。
- 肝性脑病和腹水起病后中位生存期分别为0.92年和1.1年,腹水患者自发性细菌性腹膜炎年发生率11%。
- 随机试验中非选择性β受体阻滞剂较安慰剂降低失代偿或死亡风险(16% vs 27%)。
核心结论
- 一线治疗包括卡维地洛或普萘洛尔预防静脉曲张出血、乳果糖治疗肝性脑病、醛固酮拮抗剂联合袢利尿剂治疗腹水、特利加压素治疗肝肾综合征。
研究设计与样本
- 本文为综述,汇总美国肝硬化的流行病学、病因、诊断、并发症自然史及随机临床试验与Meta分析证据。
主要发现
- 2010至2021年肝硬化年龄标化死亡率从每10万人14.9升至21.9。
- 美国肝硬化最常见病因可重叠:酒精使用障碍约占全部病例45%、非酒精性脂肪性肝病26%、丙型肝炎41%。
- 患者症状包括肌肉痉挛(患病率约64%)、瘙痒(39%)、睡眠质量差(63%)和性功能障碍(53%)。
- 约40%的肝硬化患者在出现肝性脑病或腹水等并发症时被诊断,肝性脑病和腹水起病后中位生存期分别为0.92年和1.1年。
- 腹水患者自发性细菌性腹膜炎年发生率11%、肝肾综合征年发生率8%,后者中位生存期不足2周;约1%至4%的肝硬化患者每年发生肝细胞癌,5年生存率约20%。
关键数值与推荐
- 弹性成像肝硬度≥15 kPa通常可确认肝硬化。
- 在201例门静脉高压患者的3年随机临床试验中,非选择性β受体阻滞剂(卡维地洛或普萘洛尔)较安慰剂降低失代偿或死亡风险(16% vs 27%)。
- 醛固酮拮抗剂与袢利尿剂联合较序贯起始更可能消退腹水(76% vs 56%)且高钾血症发生率更低(4% vs 18%)。
- 涉及705例患者的随机试验Meta分析中,乳果糖较安慰剂降低死亡率(8.5% vs 14%);涉及1415例患者的随机试验中,乳果糖降低显性肝性脑病复发风险(25.5% vs 46.8%)。
- 在300例患者的随机临床试验中,特利加压素改善肝肾综合征逆转率(从39%到18%)。
临床怎么用
- 一线治疗包括卡维地洛或普萘洛尔预防静脉曲张出血、乳果糖治疗肝性脑病、醛固酮拮抗剂联合袢利尿剂治疗腹水、特利加压素治疗肝肾综合征。
- 针对肝硬化症状的试验显示羟嗪改善睡眠功能障碍、腌菜卤水和牛磺酸减少肌肉痉挛、他达拉非改善男性性功能障碍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cirrhosis affects approximately 2.2 million adults in the US. From 2010 to 2021, the annual age-adjusted mortality of cirrhosis increased from 14.9 per 100 000 to 21.9 per 100 000 people. OBSERVATIONS: The most common causes of cirrhosis in the US, which can overlap, include alcohol use disorder (approximately 45% of all cases of cirrhosis), nonalcoholic fatty liver disease (26%), and hepatitis C (41%). Patients with cirrhosis experience symptoms including muscle cramps (approximately 64% prevalence), pruritus (39%), poor-quality sleep (63%), and sexual dysfunction (53%). Cirrhosis can be diagnosed by liver biopsy but may also be diagnosed noninvasively. Elastography, a noninvasive assessment of liver stiffness measured in kilopascals, can typically confirm cirrhosis at levels of 15 kPa or greater. Approximately 40% of people with cirrhosis are diagnosed when they present with complications such as hepatic encephalopathy or ascites. The median survival time following onset of hepatic encephalopathy and ascites is 0.92 and 1.1 years, respectively. Among people with ascites, the annual incidence of spontaneous bacterial peritonitis is 11% and of hepatorenal syndrome is 8%; the latter is associated with a median survival of less than 2 weeks. Approximately 1% to 4% of patients with cirrhosis develop hepatocellular carcinoma each year, which is associated with a 5-year survival of approximately 20%. In a 3-year randomized clinical trial of 201 patients with portal hypertension, nonselective β-blockers (carvedilol or propranolol) reduced the risk of decompensation or death compared with placebo (16% vs 27%). Compared with sequential initiation, combination aldosterone antagonist and loop diuretics were more likely to resolve ascites (76% vs 56%) with lower rates of hyperkalemia (4% vs 18%). In meta-analyses of randomized trials, lactulose was associated with reduced mortality relative to placebo (8.5% vs 14%) in randomized trials involving 705 patients and reduced risk of recurrent overt hepatic encephalopathy (25.5% vs 46.8%) in randomized trials involving 1415 patients. In a randomized clinical trial of 300 patients, terlipressin improved the rate of reversal of hepatorenal syndrome from 39% to 18%. Trials addressing symptoms of cirrhosis have demonstrated efficacy for hydroxyzine in improving sleep dysfunction, pickle brine and taurine for reducing muscle cramps, and tadalafil for improving sexual dysfunction in men. CONCLUSIONS AND RELEVANCE: Approximately 2.2 million US adults have cirrhosis. Many symptoms, such as muscle cramps, poor-quality sleep, pruritus, and sexual dysfunction, are common and treatable. First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome.
引用
- Tapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications: A Review. JAMA. 2023. PMID: 37159031. doi:10.1001/jama.2023.5997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。